Vida Ventures
Vida Ventures is a venture capital firm dedicated to transforming biomedical innovations into therapies that make a meaningful difference in patients' lives. The firm focuses on investing in companies that are at the forefront of biomedical advancements, particularly in the field of oncology and other life sciences sectors.
Vida Ventures
Portfolio
Aktis Oncology entered into a strategic collaboration with Lilly to discover and develop novel anticancer radiopharmaceuticals.
#Oncology
Secured $126 million financing to advance RIPTAC™ cancer therapies into the clinic for major solid tumors.
#Cancer Therapies
Launched with oversubscribed $165 million Series A financing to deliver superior biologics for solid tumors and inflammatory & immunology diseases.
#Biologics
Announced $150 million Series C financing to advance leading clinical-stage precision oncology pipeline.
#Precision Oncology
Announced closing of merger with AVROBIO and concurrent private placement of $130.7 million.
#Therapeutics
Announced $85 million Series A financing to advance next-generation, proximity-based protein therapeutics for cancer and autoimmune diseases.
#Protein Therapeutics
Key People
Managing Director